Valeant Pharmaceuticals International Inc. shares were up 4.7% in pre-market trade Monday after the company said it was on track to beat an extended deadline for first-quarter earnings results. The company said it would file its 10-Q form on or before June 10, before the July 31 deadline provided for in the company's amended credit agreement. Valeant said information about its conference call discussing first-quarter results would be provided "in due course." It also said results in the second-quarter and on would be filed "on a timely basis under the applicable rules" and reiterated recent revenue and adjusted earnings-per-share guidance for the first-quarter. The company filed a late annual report at the end of April, after accounting errors by the company required an earnings restatement. New chief executive officer Joseph Papa, the former CEO of Perrigo Co. PLC , started at Valeant last week.
Copyright © 2016 MarketWatch, Inc.